(Q35097977)

6 August 2017

1 reference

title

Current understanding of the biology of advanced bladder cancer (English)

1 reference

6 August 2017

Sana Al-Sukhun

1

1 reference

6 August 2017

Maha Hussain

series ordinal

2

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

97

1 reference

6 August 2017

issue

8 Suppl

1 reference

6 August 2017

page(s)

2064-2075

1 reference

Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

Detection of the c-myc gene product in urinary bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

Angiogenesis in urological malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

Collagen IV staining pattern in bladder carcinomas: relationship to prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

21 January 2018

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Mapping of the urinary bladder: Its impact on the concepts of bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

NATURAL HISTORY AND CLINICAL BEHAVIOR OF IN SITU CARCINOMA OF THE HUMAN URINARY BLADDER

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

The Pathology of Human Bladder Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Metastases from transitional cell carcinoma of urinary bladder

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Treatment of carcinomatous meningitis from transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Chromosome 21q22 deletion. A specific chromosome change in a new bladder cancer subgroup

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Review of chromosome studies in urological tumors. II. Cytogenetics and molecular genetics of bladder cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Characterization of chromosomal abnormalities in uroepithelial carcinomas by G-banding, spectral karyotyping and FISH analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

H-RAS, K-RAS, and N-RAS gene activation in human bladder cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

The epidermal growth factor receptor and the prognosis of bladder cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Expression of epidermal growth factor receptor in urinary bladder cancer metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Restriction fragment length polymorphism of the L-myc gene is not a prognostic factor in bladder cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

p53 and bcl-2 overexpression as associated risk factors in patients 40 years old or less with transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Lack of correlation between cisplatin-induced apoptosis, p53 status and expression of Bcl-2 family proteins in testicular germ cell tumour cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Radiotherapy alone or radiochemotherapy with platin derivatives following transurethral resection of the bladder. Organ preservation and survival after treatment of bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

The retinoblastoma gene functions as a growth and tumor suppressor in human bladder carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Altered Expression of Retinoblastoma Protein and Known Prognostic Variables in Locally Advanced Bladder Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

The p53 proto-oncogene can act as a suppressor of transformation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Implications of the p53 tumor-suppressor gene in clinical oncology.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Different tumor-derived p53 mutants exhibit distinct biological activities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

A genetic model for colorectal tumorigenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

WAF1, a potential mediator of p53 tumor suppression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Quantification of angiongenesis as an independent predictor of prognosis in invasive bladder carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Novel growth regulatory factors and tumour angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Expression of platelet-derived endothelial cell growth factor in bladder carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

The pathogenesis of cancer metastasis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

The monoclonal antibody BQ16 identifies the alpha 6 beta 4 integrin on bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Autocrine motility factor is a growth factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Detection of autocrine motility factor in urine as a marker of bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

An Immunohistochemical and Prognostic Evaluation of Cathepsin D Expression in 105 Bladder Carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Role of the matrix metalloproteinase and tissue inhibitors of metalloproteinase families in noninvasive and invasive tumors transplanted in mice with severe combined immunodeficiency

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Value of Immunohistochemical Laminin Staining in Transitional Cell Carcinoma of Human Bladder

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

DNA ploidy and P-glycoprotein expression as predictive factors of response to neoadjuvant chemotherapy for invasive bladder cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11289

7 January 2021

Identifiers

DOI

10.1002/CNCR.11289

1 reference

6 August 2017

1 reference